This technology is a pharmaceutical composition for the prevention and treatment of obesity, featuring capmatinib—a c-Met inhibitor used to treat non-small cell lung cancer with MET exon 14 skipping mutations—as its active ingredient. This compound prevents lipid accumulation in adipocytes and inhibits fat synthesis while simultaneously breaking down triglycerides into fatty acids and glycerol.
Obesity is a state where energy intake exceeds expenditure, causing excess energy to be stored as body fat. Research indicates that higher body mass indices correlate with increased prevalence of 17 out of 20 studied cancers, including leukemia, pancreatic, breast, colorectal, and liver cancer. However, there has been no drug capable of simultaneously treating cancer and suppressing obesity, making it difficult to preemptively block obesity-related cancer development.
This technology leverages capmatinib’s ability to inhibit the expression of proteins involved in fat synthesis—SREBP1, C/EBPα, FAS, and SCD1—and increase glycerol release. It is formulated to exert an anti-adipogenic effect at concentrations of 0.3–1.5 nM, which is below the 2 nM threshold for cytotoxicity. It can be formulated in various ways, from oral forms like tablets and capsules to injections and suppositories. Applicable to new anti-obesity drug development, preventive therapy for high-risk cancer groups with obesity, and expanding indications for existing anticancer drugs, this approach repurposes a clinically proven targeted therapy to reduce development time while managing both obesity and related cancer risks.
This invention was developed with support from the Ministry of Science and ICT for research on the therapeutic effects of the endogenous metabolite kynurenic acid on non-alcoholic fatty liver disease through the amelioration of endoplasmic reticulum stress.
N/A
